Skip to content
Skip to navigation menu

 

Dr Helen E Jones 


Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE.(2008) Phosphorylated insulin-like growth factor-1/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Research 68(24), 10238-46.

Knowlden JM, Jones HE, Barrow D, Gee JM, Nicholson RI, Hutcheson IR. (2008) Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Research and Treatment 111(1), 79-91.

Nicholson RI, Hutcheson IR, Jones HE, Hiscox SE, M Giles, Taylor KM, Gee JMW. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. (2007)  Reviews in  Endocrinology and Metabolic Disease  8, 241-25.

Naseem R, Davies SR, Jones HE, Wann KT, Holland IB, Campbell AK. (2007) Cytosolic Ca2+ regulates protein expression in E. Coli through release from inclusion bodies. Biochemical and Biophysical Research Communications 360(1), 33-9.

 Jones HE, Gee JMW, Barrow D, Tonge D, Holloway B, Nicholson RI. (2006) Inhibition of insulin receptor-isoform A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. British Journal of Cancer 95(2), 172-80.

Hutcheson IR, Knowlden JM, Jones HE, Burmi RS, McClelland RA, Barrow D, Gee JM, Nicholson RI. (2006) Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocrine Related Cancer 13 Suppl 1, S89-97.

Jones HE, Gee JMW, Hutcheson IR, Nicholson RI. (2006) Growth factor pathway switching: implications for the use of gefitinib and trastuzumab. Breast Cancer Online  7 (9).

Jones HE, Gee JMW, Hutcheson IR, Knowlden JM, Barrow D, Nicholson RI. (2006) Growth factor receptor interplay and resistance in cancer. Endocrine-related Cancer  13, S45-S51.

Jones HE, Gee JMW, Hutcheson IR, Nicholson RI. (2006) Insulin-like growth factor-1 receptor and resistance in breast cancer. Expert Reviews in Endocrinology and Metabolism. 1(1), 33-46.

Jones HE, Gee JMW, Taylor KM, Barrow D, Williams HD, Rubini M, Nicholson RI. (2005) Development of strategies for the use of anti-growth factor treatments. Endocrine–Related Cancer 12 Suppl 1, S173-82.

Nicholson RI, Hutcheson IR, Britton DJ, Knowlden JM, Jones HE, Harper ME, Hiscox S, Barrow D, Gee JMW. (2005) Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. Journal of Steroid Biochemistry and Molecular Biology 93(2-5), 257-62.

Jones HE, Goddard L, Gee JMW, Hiscox S, Rubini M, Barrow D, Williams S, Wakeling AE, Nicholson RI (2004) Insulin-like growth factor –1 receptor signalling and resistance to gefitinib (ZD1839; IRESSATM) in human breast and prostate cancer cells. Endocrine–Related Cancer 11, 1-22.

Jones HE, Nicholson RI, Hutcheson IR, Knowlden JM, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JMW. (2004) Endocrine resistance in breast cancer: Therapeutic intervention using signal transduction inhibitors. Advances in Breast Cancer 1(1), 3-9.

Nicholson RI, Jones HE, Gee JMW.  (2004) EGFR Inhibitors in Breast Cancer. Signal, 5, 9-13.

Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D, Gee JMW. (2004) Non-endocrine pathways and endocrine resistance: observations with anti-oestrogens and signal transduction inhibitors in combination. Clinical Cancer Research 10 (1 Pt 2), 346S-54S.

Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D,Wakeling AE, Nicholson RI. (2003) Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144(3), 1032-44.

Jones HE, Holland IB, Jacq A, Wall T, Campbell AK. (2003)Escherichia coli lacking the AcrAB multi-drug efflux pump in also lack non-proteinaceous, PHB-polyphosphate Ca2+ channels in the membrane. BBA Biomembranes 1612, 90-97.

Boutemmine D, Bouchard N, Boerboom D, Jones HE, Goff AK, Dore M, Sirois J. (2002) Molecular characterisation of canine prostaglandin G/H synthase-2 and regulation in prostatic adenocarcinoma cells in vitro. Endocrinology, 1134-43.

Jones HE, Holland IB, Campbell AK. (2002) Direct measurement of free Ca(2+) shows different regulation of Ca(2+) between the periplasm and the cytosol of Escherichia coli. Cell Calcium 32(4), 183-92.

Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM. (2002) Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Annals of the New York Academy of Sciences 963, 104-15.

Jones HE, Barrow, D, Dutkowski CM, Goddard L, Smith C, Harper ME, Nicholson RI. (2001) Effects of an EGF-R selective tyrosine kinase inhibitor and an anti-androgen on LNCaP cells: Identification of divergent growth regulatory pathways. The Prostate 49(1), 38-47.

Chapuy-Regaud S, Jones HE, Campbell AK, Trombe MC. (2001) Validation of the use of aequorin for cytoplasmic free calcium determination by chemiluminescence in Streptococcus pneumoniae. Journal of the Society for Biology 195 (3), 271-276.

Nicholson RI, Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM. (2001) Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocrine-related Cancer 8(3), 175-82.

Sala-Newby GB, Badminton MN, Evans WH, George CH, Jones HE, Kendall JM, Ribeiro A, Campbell AK. (2000) Targeted bioluminescent indicators in living cells. In: Eds. Ziegler MM, Baldwin TO, Bioluminescence and Chemiluminescence, part C, Vol 305 of Methods in Enzymology, Academic Press, San Diego, pp. 479-98.

Jones HE, Holland IB, Baker HL, Campbell AK. (1999) Slow changes in cytosolic free Ca2+ in Escherichia coli highlight two putatative influx mechanisms in response to changes in extracellular calcium. Cell Calcium 25 (3), 265-274.

Sala-Newby G, Kendall JM, Jones HE, Taylor KM, Badminton MN, Llewellyn DH, Campbell AK. (1999) Bioluminescent and chemiluminescent indicators for molecular signalling and function in living cells. In: Eds. Mason WT, Fluorescent and luminescent probes, 2nd ed. Academic Press, San Diego, pp. 251-72.

Holland IB, Jones HE, Campbell AK, Jacq A. (1999) Reconsidering the role of intracellular free Ca2+ in E. coli. Biochimie  81, 901-907.

Griffiths G, Jones HE, Eaton CL, Shimizu S, Stobart A. (1998) Effect of sesamin on growth and arachidonic acid content of neoplastic and non-neoplastic prostate epithelial cell cultures. Phytotherapy Research 12, 417-421. 

Jones HE, Nicholson RI, Dutkowski CM, Barrow D, Harper ME, Wakeling AE, Griffiths K. (1997)  A new EGF-R specific tyrosine kinase inhibitor ZM252868 indicates differences in growth control mechanisms in prostate carcinoma cell lines. International Journal of  Cancer 71, 1010-1018.

Jones HE, Eaton CL, Barrow D, Dutkowski CM, Griffiths K. (1997) Response of cell growth and retinoic acid receptor expression to retinoic acid in neoplastic and non-neoplastic prostatic cell lines. The Prostate 30, 174-182.

Jones HE, Eaton CL, Barrow D, Dutkowski CM, Gee JM, Griffiths K. (1997) Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor alpha and the expression of various growth factors in neoplastic and non-neoplastic prostatic cell lines. The Prostate 30, 219-231.

Griffiths G, Jones HE, Eaton CL, Griffiths K, Stobart AK. (1997) Effect of n-6 polyunsaturated fatty acids on growth and arachidonic acid formation in neoplastic and non-neoplastic canine prostate epithelial cell cultures. The Prostate 31, 29-36.

Jones HE, Blundell GK, Tidwell RR, Hall E, Farr SJ, Richards RJ. (1993) The accumulation of pentamidine and the toxic effects of the drug, its selected analogues and metabolites on isolated alveolar cells. Toxicology 80, 1-12.

Farr SJ, Jones HE, Blundell GK, Richards RJ. (1993) Dose-dependent distribution of 3H-pentamidine following intra-tracheal administration to rats. Xenobiotica 23(1), 53-60.

Jones HE, Bowen ID. (1993) Acid phosphatase activity in the larval salivary glands of developing Drosophila melanogaster. Cell Biology International 17(3), 305-315.

Jones HE, Harwood JL, Bowen ID, Griffiths G. (1992) Lipid composition of subcellular membranes from larvae and prepupae of Drosophila melanogaster. Lipids 27, 984-987.

Jones HE, Blundell GK, Wyatt I, John RA, Farr SJ, Richards RJ. (1992) The accumulation of pentamidine into rat lung slices and its interaction with putrescine. Biochemical Pharmacology 43(3), 431-437.

Peer-reviewed Conference Abstracts

Jones HE, Gee JMW, Barrow D, Holloway B, Tonge D, Nicholson RI. (2006) Maintenance of EGFR phosphorylation by the IGF-1R in the presence of gefitinib in lung cancer cells: co-targeting the EGFR and IGF-1R maximises anti-tumour effects. Proceedings of the 4th International Symposium on Signal Transduction Modulators in Cancer Therapy Abs. P210. Amsterdam, Netherlands.

Jones HE, Lewis I, Goddard L, Harper ME, Gee JMW, Barrow D, Nicholson RI. (2006) Protein kinase C delta signalling in DU145 human prostate cancer cells with acquired resistance to gefitinib (IRESSATM). Prostate and Prostatic Diseases (in press). British Prostate Group Meeting, 7-8 September, Cardiff, UK.

Jones HE, Goddard L, Harper ME, Smith C, Gee JMW, Barrow D, Holloway B, Wakeling AE and Nicholson RI. (2006) Protein kinase C signalling and acquired resistance to gefitinib (ZD1839; IRESSATM) in DU145 human prostate cancer cells. Prostate and Prostatic Diseases 9(3):350, 2006.  British Prostate Group Meeting, 11-12 April York, UK, 2005.

Gee JMW, Gutteridge E, Robertson JF, Wakeling AE, Jones HE, Nicholson RI. (2004) Biological markers during early treatment of tamoxifen-resistant breast cancer with gefitinib (‘Iressa’). Breast Cancer Res. Treat. 88 (suppl 1) S32, Abs 30. 27th Annual San Antonio Breast Cancer Symposium, 8– 11 Dec 2004 – San Antonio, USA.

Hutcheson IR, Gee JMW, Barrow D, Jones HE, Wakeling AE, Nicholson RI. (2004) Treatment of tamoxifen-resistant MCF-7 breast cancer cells with either gefitinib (‘Iressa’) or trastuzumab (Herceptin®) generates cross-resistant phenotypes. Breast Cancer Res. Treat. 88 (suppl 1) S145, Abs 3097. 27th Annual San Antonio Breast Cancer Symposium, 8– 11 Dec, San Antonio, USA.

Jones HE, Gee JMW, Barrow D, Wakeling AE, Guy S, Nicholson RI. (2004) De novo resistance to EGFR blockade by gefitinib (‘Iressa’, ZD1839) in colo-rectal cancer cells involves increased Insulin Receptor Isoform A signalling. European Journal of Cancer  2 102, Abs 336: 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, September, Geneva, Switzerland.

Jones HE, Gee JMW, Taylor KM, Barrow D, Guy S, Wakeling AE, Nicholson RI. (2003) Acquired resistance to gefitinib (Iressa, ZD1839) in breast cancer cells results from increased IGF1-R signalling and generates cross-resistance to trastuzumab. Proceedings of the 2nd International Symposium on Signal Transduction Modulators in Cancer Therapy, Abs. O22.  October, Amsterdam, Netherlands. (Oral presentation)

Jones HE, Goddard L, Gee JMW, Hiscox S, Harper ME, Rubini M, Barrow D, Guy S, Wakeling AE, Nicholson RI. (2003) Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; IRESSATM) in DU145 human prostate cancer cells. Proceedings of the 5th World Congress on Urological Research, London UK, September. (Oral presentation)

Nicholson RI, Jones HE, Gee JMW, Barrow D, Hiscox SE, Harper ME, Rubini M, Guy S, Wakeling A.E. (2003) Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (‘Iressa’, ZD1839) in MCF-7 human breast cancer cells. Breast Cancer Research and Treatment 82: S61. 26th Annual San Antonio Breast Cancer Symposium, 3 –6 Dec, San Antonio, USA.

Hutcheson IR, Knowlden JM, Barrow D, Jones HE, Nicholson RI. (2001) The novel ER down-regulator, Faslodex, modulates EGFR/MAPK activity in tamoxifen-resistant MCF-7 breast cancer cells.  Clinical Cancer Research.  7: 622. AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics, 29 Oct – 2 Nov Miami, Florida, USA.